{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:50Z","timestamp":1793664830348,"version":"4.5.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ekir.2024.12.012","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T13:53:25Z","timestamp":1734443605000},"page":"753-761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies"],"prefix":"10.1016","volume":"10","author":[{"given":"Maxime","family":"Teisseyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Cremoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Belvederi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Accinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Duquesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounir","family":"El Ma\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Brglez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Benzaken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.M.","family":"Esnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir Singh","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero Lino","family":"Cirami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.12.012_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.012_bib2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.12.012_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.012_bib4","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.12.012_bib6","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib9","first-page":"879","article-title":"Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy","volume":"45","author":"Schroff","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.ekir.2024.12.012_bib10","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1073\/pnas.86.11.4220","article-title":"Mouse\/human chimeric monoclonal antibody in man: kinetics and immune response","volume":"86","author":"LoBuglio","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2024.12.012_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2024.12.012_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2024.12.012_bib13","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","article-title":"Antidrug antibody formation in oncology:\u00a0clinical relevance and challenges","volume":"21","author":"van Brummelen","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ekir.2024.12.012_bib14","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib15","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib16","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2024.12.012_bib17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4049\/jimmunol.2300647","article-title":"Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies","volume":"212","author":"Rispens","year":"2024","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib19","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","article-title":"Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy","volume":"6","author":"Teisseyre","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.012_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in\u00a0vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2024.12.012_bib21","first-page":"51","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"3","author":"Lin","year":"2010","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.ekir.2024.12.012_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.ekir.2024.12.012_bib23","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.18632\/oncotarget.27691","volume":"11","author":"Chu","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ekir.2024.12.012_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.13764","volume":"171","author":"Awasthi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2024.12.012_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2024.12.012_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.ekir.2024.12.012_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: A report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.12.012_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000501858","article-title":"Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: preliminary findings with double filtration plasmapheresis and ofatumumab","volume":"144","author":"Podest\u00e0","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2024.12.012_bib29","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.012_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","article-title":"Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases","volume":"23","author":"Hudson","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00467-023-06085-8","article-title":"A\u00a0child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance","volume":"39","author":"Conversano","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ekir.2023.01.035","article-title":"Obinutuzumab in refractory phospholipase A2 receptor-associated membranous nephropathy with severe CKD","volume":"8","author":"Naik","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.012_bib33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.012_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib36","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2024.12.012_bib37","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.kint.2020.12.029","article-title":"Personalized phospholipase A2 receptor antibody\u2013driven rituximab treatment strategy in membranous nephropathy","volume":"99","author":"Delafosse","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.012_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ekir.2023.10.023","article-title":"Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence","volume":"9","author":"Destere","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.012_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.12.012_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2024.12.012_bib41","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.ekir.2024.12.012_bib42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","article-title":"Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome","volume":"37","author":"Bertrand","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamadermatol.2022.2149","article-title":"Evaluation of clinical relevance and biological effects of Antirituximab antibodies in patients with pemphigus","volume":"158","author":"Lemieux","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ekir.2024.12.012_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.ekir.2024.12.012_bib45","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","article-title":"Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome","volume":"7","author":"Angeletti","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.12.012_bib46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00467-020-04629-w","article-title":"Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome","volume":"35","author":"Fujinaga","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.ekir.2024.12.012_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8958-4_1","article-title":"Human monoclonal antibodies: the benefits of humanization","volume":"1904","author":"Waldmann","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ekir.2024.12.012_bib49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ekir.2024.12.012_bib50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2024.12.012_bib51","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ekir.2024.12.012_bib52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.12.012_bib53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood-2015-03-634394","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2024.12.012_bib54","first-page":"1463","article-title":"Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders","volume":"17","author":"Said","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ekir.2024.12.012_bib55","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2024.12.012_bib56","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","article-title":"Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study","volume":"119","author":"Czuczman","year":"2012","journal-title":"Blood"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924034132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924034132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:32:32Z","timestamp":1744864352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924034132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2468024924034132"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.012","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}